Clinical trial · no report yet · Phase 2
NCT06138769
Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
- NCT06138769 ↗
- Active, not recruiting
- Asan Medical Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Multicenter Phase 2 Trial of Lenvatinib in Patients With Unresectable or Metastatic Hepatocellular Carcinoma After Progression on First-line Atezolizumab Plus Bevacizumab
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Lenvatinib
- Arms
- Lenvatinib · Experimental
- Enrollment
- 50
- Primary outcomes
- Progression-free survival
- Sponsor
- Asan Medical Center with Eisai Inc., Chonnam National University Hospital, Seoul National University, Gangneung Asan Hospital, Ulsan University Hospital, Chosun University Hospital, Dong-A University Hospital, Bundang CHA Hospital, Seoul National University Bundang Hospital, Yonsei University, Hanyang University Seoul Hospital, Chungnam National University Hospital, Saint Vincent's Hospital, Korea, Gyeongsang National University Hospital, Ewha Womans University, Chungbuk National University Hospital, Severance Hospital, Gachon University Gil Medical Center, The Catholic University of Korea, Bucheon St. Mary's Hospital
- Start
- Jul 20, 2023
- Primary completion
- Nov 1, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06138769 · updated Jul 3, 2024
Publications
linked from the registry- Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PubMed 29433850
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. PubMed 32402160
- Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308. No abstract available. PubMed 30285213
- Kim HD, Sym SJ, Chon HJ, Kim M, Kang JH, Ryoo BY, Lee CK, Hong J, Ryu H, Bae WK, Kim H, Kim H, Kim JW, Kim TY, Yoo C. Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab. J Hepatol. 2026 Feb;84(2):308-315. doi: 10.1016/j.jhep.2025.08.020. Epub 2025 Sep 4. PubMed 41038766